TORONTO – Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”), a consumer packaged goods company in the cannabis products market, is thrilled to announce that its wholly owned subsidiary, KGK Science Inc. (“KGK”) has received its second Cannabis Research Licence from Health Canada pursuant to the Cannabis Act. This licence permits KGK to administer cannabis extracts, edible cannabis and cannabis topicals to human subjects for purposes of palatability and sensory testing at its clinical research facility located in London, Ontario.
Sensory evaluation measures, analyzes and interprets the reaction of human subjects to products as perceived by the senses, it is an incredibly valuable tool in understanding and determining consumer preferences and the basis for those differences. As the cannabis industry continues to expand and new products are being introduced to the market, KGK will be able use their existing database of over 25,000 participants to provide palatability and sensory studies to all licenced producers across Canada that are seeking to undertake controlled focus groups on any cannabis product development initiatives.
Hugo Alves, CEO of Auxly stated: “This exciting and strategic milestone further expands and establishes KGK’s presence and leadership role in the cannabis industry. Their remarkable science team and commitment to ensuring safe and effective cannabis products for Canadian consumers is what continues to set them apart. We couldn’t be more proud of the KGK team!”
“Securing this license is another step towards maintaining our commitment to provide leading research to support growth in the cannabis industry,” says KGK President and CEO Najla Guthrie. “Facilitating the evaluation of cannabis products aligns with our decades of experience implementing cutting-edge clinical science to help companies bring safe and effective natural health products to market. We look forward to contributing to the success of innovative, consumer-tested cannabis products for the Canadian cannabis industry.”
ON BEHALF OF THE BOARD
“Hugo Alves” CEO
About Auxly Cannabis Group Inc. (TSX.V: XLY)
Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market. Learn more at www.auxly.com
About KGK Science Inc.
KGK Science, a wholly owned subsidiary of Auxly, is a premium contract research organization (CRO) offering high-quality clinical research trials and expert regulatory support for the nutraceutical, cannabis and hemp industries. For over 22 years, KGK has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies that move products efficiently into global markets. Equipped with state-of-the-art technologies, novel research techniques, and a seasoned team of industry experts, KGK Science remains at the forefront of its industry, consolidating scientific, clinical, commercial, and regulatory expertise with innovation and agility to serve the expanding needs of global business and consumers. Visit us at www.kgkscience.com
